Revance Therapeutics (RVNC)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
| 09-2014 | 06-2014 | 03-2014 | 12-2013 | 09-2013 | |
| Sales | 75 | 75 | 158 | 309 | 158 |
| Gross Profit | 75 | 75 | 158 | 309 | 158 |
| Operating Expenses | 13,900 | 12,967 | 11,644 | 9,241 | 8,426 |
| Operating Income | -13,825 | -12,892 | -11,486 | -8,932 | -8,268 |
| Interest Expense | 228 | 267 | 9,841 | 1,699 | 351 |
| Other Income | 76 | -143 | -99 | 552 | -264 |
| Pre-tax Income | -13,977 | -13,302 | -21,426 | -10,079 | -8,883 |
| Net Income Continuous | -13,977 | -13,302 | -21,426 | -10,079 | -8,883 |
| Net Income | $-13,977 | $-13,302 | $-21,426 | $-10,079 | $-8,883 |
| EPS Basic Total Ops | -0.60 | -0.69 | -1.93 | 106.80 | -55.92 |
| EPS Basic Continuous Ops | -0.60 | -0.69 | -1.93 | -36.77 | -38.83 |
| EPS Diluted Total Ops | -0.60 | -0.69 | -1.93 | 111.22 | -55.92 |
| EPS Diluted Continuous Ops | -0.60 | -0.69 | -1.93 | 78.45 | -38.83 |
| EBITDA(a) | $-13,158 | $-12,238 | $-9,900 | $-7,132 | $-7,737 |